While the world’s fight against the coronavirus epidemic continues, there has been a development that will be talked about a lot in the USA. A company called Gritstone, which has started to be supported by the US National Institute of Health, announced that it has developed a new coronavirus vaccine. The vaccine named “GRT-R910”, which uses a similar production technique of mRNA-based vaccines, draws attention with its protectiveness against all variants.
The COVID-19 vaccine produced by Gritstone develops on its own after being injected into the body. This provides immunity against possible coronavirus variants. The scientists behind the vaccine state that GRT-R910, which is more effective than mRNA vaccines at much lower doses, has also reduced the possibility of side effects thanks to this feature. According to experts, the new vaccine developed is a much more advanced version of the vaccines developed by companies such as Moderna or BioNTech.
It can even be produced in hospitals.
Gritstone officials explained that the vaccine was administered to 20 people aged 60 and over and they are working to analyze the results, while company CEO Dr. Andrew Allen, on the other hand, said, “It will make a much greater contribution than the extra vaccine of the same vaccine brand.” Stating that the vaccine, which is also very affordable in terms of cost, does not need advanced systems, scientists state that GRT-R910 can be produced even in hospitals. Moreover, if the coronavirus ends and another virus outbreak occurs, a vaccine can be developed for the new epidemic with the technique of GRT-R910.
The vaccine, which excites the scientific world and is thought to be the definitive solution against the epidemic, still needs to be tested for a long time before it can be applied. However, considering that there will be no problems with the theoretical examinations, it seems that this process can be accelerated. Perhaps Gritstone’s COVID-19 vaccine will be a life saver for all future outbreaks. . .
33090
